Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel

Background. Men with metastatic castrate-resistant prostate cancer (mCRPC) may not receive docetaxel in everyday clinical practice due to comorbidities. Here we explore the impact of comorbidity on outcome in men with mCRPC treated with docetaxel in a population-based outcome study.

Bibliographic Details
Main Authors: Zist Andrej, Amir Eitan, Ocana Alberto F., Seruga Bostjan
Format: Article
Language:English
Published: Sciendo 2015-12-01
Series:Radiology and Oncology
Subjects:
metastatic castration-resistant prostate cancer
comorbidity
chemotherapy
Online Access:https://doi.org/10.1515/raon-2015-0038

Similar Items

Similar Items